Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

Chao Niu; Hunjun Xie; Haji Akber Aisa

doi:10.2174/1389557521666210325120233

Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

Mini Rev Med Chem. 2021;21(20):3203-3218. doi: 10.2174/1389557521666210325120233.

Authors

Chao Niu¹, Hunjun Xie², Haji Akber Aisa²

Affiliations

¹ State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization and Key Laboratory of Plant Resources and Chemistry of Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China | University of Chinese Academy of Sciences, Beijing, 100049, China | Nantong Chanyoo Pharmatech Co., Ltd., Nantong 226407, China.
² State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization and Key Laboratory of Plant Resources and Chemistry of Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China | University of Chinese Academy of Sciences, Beijing, 100049, China.

PMID: 33823765
DOI: 10.2174/1389557521666210325120233

Abstract

The small-molecular inhibitors targeted JAks (JAK inhibitors) could modulate the cytokines- mediated signaling via the JAK-STAT pathway, which plays an important role in immune regulation and cell proliferation. The JAK inhibitors were previously designed and synthesized to treat diseases involving the hematologic and immune system. Increasing evidence shows that they are quite effective in Atopic Dermatitis (AD), Alopecia Areata (AA), psoriasis, vitiligo, and other autoimmuneinduced dermatologic conditions. Currently, many JAK inhibitors possessing anti-vitiligo activity are being investigated in the laboratory and clinically. In this view, we would like to summarize the applications of these inhibitors with emphasis on the profile of vitiligo, clinical efficacy, dosages, development of new candidates and adverse events through available literature.

Keywords: JAK inhibitors; JAK-STAT; dermatologic conditions; ruxolitinib.; tofacitinib; vitiligo.

Publication types

Review

MeSH terms

Humans
Janus Kinase Inhibitors* / adverse effects
Janus Kinases / metabolism
Janus Kinases / pharmacology
STAT Transcription Factors / pharmacology
STAT Transcription Factors / therapeutic use
Signal Transduction
Vitiligo* / chemically induced
Vitiligo* / drug therapy

Substances

Janus Kinase Inhibitors
STAT Transcription Factors
Janus Kinases

Abstract

Publication types

MeSH terms

Substances

Grants and funding